BRISBANE, May 29, 2019 (GLOBE NEWSWIRE via COMTEX) -- CareDx, Inc. /zigman2/quotes/200138382/composite CDNA -3.89% , a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will showcase 12 abstracts and host a dynamic lunch symposium during the American Transplant Congress June 1- 5, 2019 in Boston, MA.
CareDx will formally announce KidneyCare during a lunch symposium alongside transplant key opinion leaders on Tuesday, June 4th. KidneyCare combines clinically validated AlloSure testing with AlloMap Kidney and iBox to deliver personalized and prognostic solutions for transplant patients.
"Building on the momentum of AlloSure, there is incredible potential for KidneyCare to enable us to tailor treatment for kidney transplant patients. The value is not only to identify when there may be an issue, but to reduce immunosuppression in a subset of patients," said Ram Peddi, MD, Transplant Nephrologist at California Pacific Medical Center. "We are excited to bring personalized medicine to transplantation with KidneyCare."
Seven leaders in transplantation will speak during the CareDx Lunch Symposium titled Better Transplant Outcomes Start with Better Transplant Surveillance, on June 3at 1pm EST in the Grand Ballroom of the Sheraton Hotel in Boston:
-- Matthew Weir, MD, University of Maryland
-- Alexandre Loupy, MD, PhD, Paris Transplant Group
-- Vikas Dharnidharka, MD, MPH, Washington University
-- Daniel C. Brennan, MD, FACP, Johns Hopkins Hospital
-- Stanley C. Jordan, MD, FASN, FAST, Cedars-Sinai Transplant Center
-- Tarek Alhamad, MD, MS, FACP, FASN, Barnes Jewish Hospital, Washington
-- Anthony Langone, MD, FAST, Vanderbilt University Medical Center
CareDx will host a press conference following the lunch symposium at 4pm in the Sheraton Hotel with Anthony Langone, MD and Alexandre Loupy, MD, PhD.
CareDx services will also be featured in 4 oral and 8 poster presentations in the main ATC programming.
Correlation of Donor-Derived Cell-Free DNA with Histology and Molecular Diagnoses of Kidney Transplant Biopsies. I. Moinuddin, Virginia Commonwealth University Medical Center
Donor Derived Cell Free DNA is Associated with De-Novo Donor Specific Antibody (DSA) Responses. S. Jordan, Cedars-Sinai Medical Center
Elevated Donor Derived Cell Free DNA (dd-cfDNA) Levels in the Presence of Donor Specific Antibodies (DSA) Are a Strong Predictor of Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients. D. Puliyanda, Cedars-Sinai Medical Center
The Use of dd-cfDNA as a Predictive Tool for Outcome Decreased Kidney Function. T. Alhamad, Washington University School of Medicine
Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients. R. Swinford, University of Texas at Houston
Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients, Can We Extrapolate from Kidney Transplant Alone? O. Olaitan, Rush University Medical Center